Abstract
As newer, molecularly targeted, anticancer drugs are entering clinical practice, a wide array of previously unrecognised and ill defined side effects of these drugs are increasingly observed. Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis. In this review, we shall deal with these poorly recognised, but sometimes extremely distressing, toxicities; pathophysiologic mechanisms will be discussed and suggestions for treatment of each toxicity will be proposed, based on the few pieces of evidence available and, especially, on our empirical experience.
| Original language | English |
|---|---|
| Pages (from-to) | 127-134 |
| Number of pages | 8 |
| Journal | Clinical and Experimental Medicine |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 2007 |
Fingerprint
Keywords
- Dermatitis
- Hand-foot skin reaction
- Hypertension
- Sorafenib
- Sunitinib
- Toxicity
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Clinical Biochemistry
- Medicine(all)
Cite this
Uncovering Pandora's vase : The growing problem of new toxicities from novel anticancer agents. the case of sorafenib and sunitinib. / Porta, C.; Paglino, C.; Imarisio, I.; Bonomi, L.
In: Clinical and Experimental Medicine, Vol. 7, No. 4, 07.2007, p. 127-134.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Uncovering Pandora's vase
T2 - The growing problem of new toxicities from novel anticancer agents. the case of sorafenib and sunitinib
AU - Porta, C.
AU - Paglino, C.
AU - Imarisio, I.
AU - Bonomi, L.
PY - 2007/7
Y1 - 2007/7
N2 - As newer, molecularly targeted, anticancer drugs are entering clinical practice, a wide array of previously unrecognised and ill defined side effects of these drugs are increasingly observed. Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis. In this review, we shall deal with these poorly recognised, but sometimes extremely distressing, toxicities; pathophysiologic mechanisms will be discussed and suggestions for treatment of each toxicity will be proposed, based on the few pieces of evidence available and, especially, on our empirical experience.
AB - As newer, molecularly targeted, anticancer drugs are entering clinical practice, a wide array of previously unrecognised and ill defined side effects of these drugs are increasingly observed. Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis. In this review, we shall deal with these poorly recognised, but sometimes extremely distressing, toxicities; pathophysiologic mechanisms will be discussed and suggestions for treatment of each toxicity will be proposed, based on the few pieces of evidence available and, especially, on our empirical experience.
KW - Dermatitis
KW - Hand-foot skin reaction
KW - Hypertension
KW - Sorafenib
KW - Sunitinib
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=38349030422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38349030422&partnerID=8YFLogxK
U2 - 10.1007/s10238-007-0145-8
DO - 10.1007/s10238-007-0145-8
M3 - Article
VL - 7
SP - 127
EP - 134
JO - Zeitschrift für Die Gesamte Experimentelle Medizin
JF - Zeitschrift für Die Gesamte Experimentelle Medizin
SN - 1591-8890
IS - 4
ER -